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Abstract
Background: Irritable bowel syndrome (IBS) is a worldwide disease with high morbidity. The effect of current
treatment with Western medicine is not satisfactory. Although moxibustion treatment is widely used for
gastrointestinal diseases, randomized controlled trials on the use of this treatment for IBS are limited. This
study aims to evaluate the clinical efficacy and safety of moxibustion treatment in patients with diarrhea-
predominant irritable bowel syndrome (IBS-D).
Methods/design: A multi-center, randomized, single-blind and placebo-controlled trial is employed. 104 cases will be
divided into two groups: (1) a mild-warm moxibustion group in which moxa stick is 3–5 cm away from acupuncture
points and the skin temperature is maintained at 43 ± 1 °C; and (2) a placebo moxibustion group in which moxa stick
is 8–10 cm away from acupuncture points and the skin temperature is maintained at 37 ± 1 °C. Moxibustion is
performed on bilateral ST25 and ST36 in the two groups for 30 min each time, three times a week for 6 weeks. The
patients are followed up at the 12th and 18th weeks. Adequate relief is used as a primary outcome measure; IBS
symptom severity score, Bristol stool form scale, IBS quality-of-life questionnaire, and hospital anxiety and depression
scale are used as secondary outcome measures.
Discussion: This study aims to demonstrate the safety and efficacy of moxibustion treatment for IBS-D, which may
validate moxibustion as an effective therapy for treating IBS-D.
Trial registration: ClinicalTrials.gov identifier NCT02421627 (8 April 2015).
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Background
Irritable bowel syndrome (IBS) is a chronic functional
gastrointestinal disorder characterized by recurrent
abdominal pain or discomfort in combination with
disturbed bowel habits in the absence of an identifiable
cause [1]. Currently, the morbidity of IBS is 7–21 %
worldwide, it can occur at any age, mainly between 30
and 50 years [2, 3]. Of all types, diarrhea-predominant
irritable bowel syndrome (IBS-D) is the most common
subtype [4]. IBS has gained attention because it signifi-
cantly reduces people’s quality of life (QOL) and influ-
ences medical resources and social economy [5, 6].
The pathogenesis of IBS is unclear. It is probably
related to visceral hypersensitivity, brain–gut regulation
dysfunction, intestinal infection and inflammation, and
psychological factors [2, 7]. The current treatment for
IBS is to remove the inducing factors and relieve the
symptoms. However, the poor efficacy and the side
effects from long-term drug use have forced patients to
seek alternative interventions [8, 9]. In recent years,
physicians as well as patients are more interested in
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complementary and alternative medicine including acu-
puncture and moxibustion [10, 11]. While much less
popular than acupuncture, moxibustion exerts its effects
through warm stimulation caused by burning moxa on
the acupuncture points. Mild-warm moxibustion is a
therapy in which a burning moxa stick is pointed to a
moxibustion site (usually an acupuncture point) at a dis-
tance to make the patient have a warm sensation but
without any burning pain. Because of its low cost and
easy application, moxibustion is often used to treat
gastrointestinal diseases. However, its efficacy on IBS has
not been confirmed. Previous trials on the treatment of
IBS with moxibustion were often lack of strict control of
randomization and related risk of bias, which makes the
conclusions less convincing [12]. A recent randomized
controlled trial on herb-partitioned moxibustion for IBS
also failed to fully confirm its effectiveness, and the
results still need to be verified [13].
Therefore, a multi-center, parallel-group, 1:1 alloca-
tion, randomized, single-blind and placebo-controlled
trial has been designed in this study. The aim is to evalu-
ate the clinical efficacy and safety of moxibustion in pa-
tients with IBS-D. The results may provide evidence for
the clinical use of moxibustion in patients with IBS-D.
Methods/design
Study design
This study is a multi-center, randomized, single-blind
and placebo-controlled clinical trial. All the subjects will
be enrolled according to the ROME III IBS-D diagnostic
criteria [14]. The flowchart of the trial is shown in Fig. 1.
Patients
All the 104 cases will be recruited from the following three
research centers: the Bowel Disease Clinic of the Shanghai
Research Institute of Acupuncture and Meridian; the
Department of Acupuncture-Moxibustion of the Yueyang
Integrated Chinese and Western Medicine Hospital at the
Shanghai University of Traditional Chinese Medicine
(TCM); and the Department of Acupuncture-Moxibustion
of the Shanghai TCM-Integrated Hospital, Shanghai
University of TCM. Recruitment notices were released on
TV, newspapers, and magazines. Also, recruiting posters
were posted in the community and public places nearby to
ensure enough subjects.
Sample size calculation
Previous studies showed that the effective rates of the
mild-warm moxibustion group and the placebo group
were 88.7 % [15] and 62 % [16], respectively. Based on
these values, the sample size in this study is estimated as
follows:
n ¼ Uaþ Ubð Þ2 1 þ 1=kð ÞP 1−Pð Þ= Pe−Pcð Þ2
The significant level is 0.05; the power of test is 1
− β = 0.9, k = 1; and the sample loss rate is 15 %. The
Fig. 1 Flow diagram of study design
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required sample size is 52 by calculation, and no less
than 104 cases should be included in the two groups.
Randomization
In this study, random numbers are generated by SPSS
and kept by a clinical research coordinator who has no
contact with the patients. The allocation will be con-
cealed in sequentially numbered, opaque, sealed enve-
lopes containing the randomization assignments. An
eligible subject who meets the inclusion criteria will sign
the informed consent. Researchers in a research center
will use a random number and grouping information
sent by telephone, text message, or e-mail from the clin-
ical research coordinator, and assign the subject into
moxibustion or placebo moxibustion groups.
Blinding
The practitioners could not be blinded due to the unique
nature of moxibustion treatments. The patients are
blinded to the treatment. They are kept in individual
isolated rooms, avoiding communication among them.
Furthermore, Researchers responsible for data collection,




 Patients who are enrolled according to the ROME
III IBS-D diagnostic criteria
 Patients aged between 18 and 65 years
 Patients who have signed informed consent
Exclusion criteria:
 Patients who present with intestinal organic
disorders
 Patients who have been administered drugs for
treating IBS-D or other drugs that may influence the
trial
 Patients who have a severe disease of the heart,
brain, lung, liver, kidney, or hematopoietic system
 Patients who are diagnosed with a psychiatric
disorder
 Women in pregnancy or nursing
 Patients who have a history of abdominal surgery




For mild-warm moxibustion treatment, bilateral ST25 and
ST36 points are used (reference for PRC National Stand-
ard GB/T 12346–2006) [17]. A moxa stick (diameter
3 cm) is ignited and positioned with a supporting device
so that the tip of the moxa stick is 3–5 cm above the acu-
puncture point. The temperature of the acupuncture point
is monitored with an infrared thermometer (Fluke 62,
USA) and maintained at 43 ± 1 °C to make the subject feel
warm without any burning pain. The treatment lasts for
30 min each time, three times a week for 6 weeks (18
times). After the treatment, follow-ups are made at weeks
12 and 18.
Control group
For the placebo moxibustion group, the same acupunc-
ture points as the treatment group are used. The same
type of moxa stick is ignited but kept 8–10 cm above
the acupuncture point. The temperature of the acupunc-
ture point is similarly monitored but maintained at 37 ±
1 °C so that the subjects do not to feel warm at the
points. The treatment cycle and follow-up time are the
same as the treatment group.
Outcome measurements
Primary outcome
Adequate relief Adequate relief (AR) is used to evaluate
the degree of alleviation of IBS symptoms, with relief of
abdominal pain or abdominal discomfort as the criter-
ion. During the treatment and follow-up, the patients
evaluate themselves once every week. The primary end-
point is set at the end of the treatment (week 6), and the
statistics are also performed during follow-ups (weeks 12
and 18) for efficacy duration assessment. “Yes” is defined
as positive symptom improvements in more than 3 weeks
during the 6-week period; “no” is defined as positive
symptom improvements in less than 3 weeks [18]. The
indicator has been applied in several studies [19, 20] and
was found to have significant correlations with intestinal
function and QOL [21].
Secondary outcomes
IBS Symptom severity score IBS symptom severity
score (SSS) [22] is used to evaluate the degree of severity
of IBS-D in the patients. A total score of 500 is calcu-
lated from abdominal pain degree, abdominal pain
frequency, abdominal distension degree, defecation satis-
faction, and influence on life. If the score is lower than
75, the patient is considered to be in remission. The
mild, moderate, and severe boundary values are 75–175,
175–300, and above 300, respectively. The effectiveness,
reliability, and sensitivity of IBS SSS to treatment are
verified.
Bristol stool form scale Grading standard in the Bristol
stool form scale (BSS) [23] is employed to record stool
characteristics of the patients with IBS-D in this study. The
scale is a visual descriptive figure reflecting gastrointestinal
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transit time. The total score of the scale ranges from 1 to 7
according to the 1–7 types (from constipation to diarrhea)
of stool characteristics.
Irritable bowel syndrome quality-of-life question-
naire Irritable bowel syndrome quality-of-life question-
naire (IBS-QOL) is a specialized scale developed by
Patrick et al. [24] for patients with IBS. It is composed
of 34 items of self-assessment ranging from dysphoria,
interference with activity, body image, health worry, food
avoidance, social reaction, to sexual relationships, to as-
sess QOL. The patients’ QOL is measured by a 5-point
linear scale, and each question has a 5-point Likert scale
(score 1–5). The total score of the scale ranges from 34
to 170. The scale achieves good measurement validity.
Hospital anxiety and depression scale Hospital anxiety
and depression scale (HADS) is used to assess the level
of anxiety and depression in patients with IBS-D [25]. It
comprises 14 questions, with seven questions each on
anxiety and depression. Each question has a 4-point
Likert scale (score 0–3). The total score of the scale
ranges from 0 to 42. A score greater than 8 in each sub-
scale indicates anxiety/depression.
IBS-SSS and BSS are completed before treatment
(week 0), at the end of treatment (week 6), and
during follow-ups (weeks 12 and 18). IBS-QOL and
HADS are completed before treatment (week 0) and
at the end of treatment (week 6). All the assessments
are shown in Table 1.
Safety outcome
In this study, possible adverse events during moxibus-
tion include skin burns, blisters, pruritus, dizziness, and
respiratory symptoms. The researchers record and deal
with all the adverse events (no matter whether it is rele-
vant with moxibustion). When necessary, the researchers
can decide whether the trial is terminated.
Quality control
All the researchers are practicing doctors certified by the
Ministry of Health of the People’s Republic of China.
They must have more than 5 years of clinical experience
and be qualified as attending physicians. All the re-
searchers are trained to improve consistency among sub-
jects. The outcomes are assessed for all the subjects. The
outcome measurement data are preserved in the original
case report form (CRF), and supervised and checked by
a qualified clinical research coordinator. The original
data are recorded into the electronic medical records
using a double data entry method by trained researchers,
and the electronic data are consistent with the original
data. To improve compliance of the subjects, each sub-
ject who completes the trial is provided a cash reward.
Data monitoring
This study has set up an independent clinical trial data
monitoring committee (DMC), which comprises a medical
expert and two clinical research experts. The DMC veri-
fies whether the trial follows the study design and the
standard guidelines, checks research progress and the
Table 1 Trial flowchart
Items Before enrolment



























AR × × × × × ×
Secondary
outcomes
SSS × × × ×
BSS × × × ×
IBS-QOL × ×
HADS × ×
Safety outcome × × ×
Statistical analysis × × ×
Bao et al. BMC Complementary and Alternative Medicine  (2016) 16:408 Page 4 of 6
accuracy and authenticity of the CRF, and checks whether
the reasons for discontinuation of subjects and adverse
events have been recorded in detail in the CRF. In the case
of any serious adverse events, the DMC discusses with the
institutional review board and the principal investigator,
and the principal investigator makes a final decision on
the continuation or termination of the trial. In addition,
the institutional review board also makes recommenda-
tion to the principal investigator on stopping the trial if a
serious adverse event occurs.
Statistical analysis
The statisticians are responsible for coordinating research
efforts, making a statistical analysis plan, and building a
research database. Both intention-to-treat and per-
protocol analyses are performed. The last-observation-
carried-forward method is used for missing data in the
intention-to-treat analysis. SPSS16.0 software is used to
analyze the data. Measurement data are first tested using
the normality test. Data conforming to the normal distri-
butions are expressed as mean ± standard deviation, while
data not conforming to the normal distributions are
expressed as M (P25–P75). A paired t test or nonparamet-
ric test is used to perform intragroup comparison, and a
two-sample t test or nonparametric test is used to perform
comparison among groups. Enumeration data is expressed
as a case (ratio) and analyzed using the χ2 test. Statistic
significance is defined as p < 0.05.
Discussion
The present study assesses the efficacy and safety of
mild-warm moxibustion treatment in patients with IBS-
D through a multi-center, randomized, single-blind and
placebo-controlled trial.
To confirm the efficacy of mild-warm moxibustion,
placebo moxibustion is used as control which is included
to eliminate potential placebo effect of moxibustion
treatment. Methods for designing a placebo control
group for mild-warm moxibustion were limited in the
past. One study [26] used a 0.5 cm diameter moxa cone
as a placebo in a blind trial. However, this method is im-
practical in our research design because the moxa stick
used for warm moxibustion has to be longer than
1.5 cm which is also the most widely used specification
in clinical practice.
At least two conditions should be satisfied in the de-
sign of placebo-controlled moxibustion: one is that the
placebo model has no specific therapeutic function, the
other is that subjects cannot perceive the difference be-
tween the placebo moxibustion and the real one. It has
been proved that thermal stimulation is an important
factor that influences the treatment efficacy, as the heat
must reach a certain level to exert the effect [27, 28]. In
this study, we use a moxa stick of 3 cm diameter to
achieve better efficacy through stimulating the acupunc-
ture points for more heat. Due to the unique nature of
moxibustion treatment, if the heat stimulus was fully
shielding, the participants will not be well blinded.
Therefore, we try to reduce the heat stimulation of
moxibustion to a minimum, while blind to the partici-
pants. The distance of the moxa stick to the acupuncture
points in the placebo control group is set to 8–10 cm,
and the temperature of the acupuncture point is main-
tained at 37 ± 1 °C. At this temperature, the subjects will
feel “lukewarm”, because the temperature of human skin
is between 30 and 36 °C with the average temperature at
33.5 ± 0.5 °C. In contrast, the distance of the moxa stick
to the acupuncture points in the treatment group is set
to 3–5 cm, so that the subjects feel warm without any
burning pain. The temperature of the acupuncture point
is maintained at 43 ± 1 °C, which is shown to contribute
to the efficacy of moxibustion treatment [29]. It is im-
portant to mention that the subjects will be enrolled
with no history of acupuncture and moxibustion treat-
ment, and are not aware of the manipulation of moxi-
bustion. Furthermore, they will be treated in individual
isolated rooms, which prevent them from communicat-
ing with each other. Hence, the environment is condu-
cive to perform the trial.
A limitation of the trial is that the study cannot
double-blind the physicians and subjects. Thus, potential
subjective factors in the clinician’s approach to the task
and possible awareness of the subjects about the treat-
ment they receive may lead to bias of the study.
The present protocol may demonstrate moxibustion as
a safe and effective treatment for patients with IBS-D. If
the goals of the study are achieved, we will provide new
evidence that moxibustion may be an effective therapy
for treating IBS-D. The low-cost, easy-applicable treat-
ment will reduce the financial burden for the patients
and healthcare system, relieve the medical burden of
hospitals and save medical resources.
Trial status
The trial is currently in the recruitment phase. Partici-
pant recruitment started in April 2015, and is expected
to end in December 2017.
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